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The alternative  pathway of human  complement serves  as a  humoral  recognition 
mechanism in a  nonimmune host for cell surfaces presented  by a  variety of bacteria 
(1-4),  fungi  (5,  6), parasites  (7),  and heterologous  (8-10),  virus-infected  (11,  12),  or 
neoplastic  (13,  14)  mammalian  cells.  The  continuous  low-grade  interaction  of the 
alternative pathway components C3, B, I), and properdin  (p)l  (15,  16) generates the 
major  cleavage  fragment  of C3,  C3b,  which  may  attach  covalently  to  bystander 
surfaces  (17).  Particle-bound  C3b  binds  B  in  a  Mg++-dependent  reaction  (18)  and 
subsequent  cleavage of B  by I) generates  the amplification  convertase,  C3b,Bb  (19, 
20),  which is stabilized  by the uptake of P  (21).  Whether a  particle  is  activating or 
nonactivating is  determined  by the  relative  capacity of its  surface  to assemble  and 
maintain  the function of the amplification convertase in the presence of the control 
proteins, ~IH and C3b inaetivator (C3bINA) (22, 23). One biochemical characteristic 
that determines  the capacity of a  particle surface to activate the human alternative 
complement  pathway  is  a  relative  deficiency  of sialic  acid  (24,  25).  Sialic  acid 
promotes  high-affinity  association  between  particle-bound  C3b  and  /~IH  without 
influencing the affinity of C3b for B, and thus impairs the formation of the amplifi- 
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1  Abbreviations used in this paper." C3bINA, C3b inactivator; CNBr, cyanogen bromide; DGVB  ÷÷, half- 
isotonic GVB  ++ with 2.5% dextrose; GVB, Veronal-buffered saline, containing 0.1% gelatin; GVB  ÷÷, GVB 
containing 0.15 mM calcium and 0.5 mM magnesium; GVB-EDTA, GVB containing 0.04 M EDTA; 
GVB-Mg-EGTA, GVB containing 2 mM magnesium and 8 mM EGTA; NHS-EDTA, normal human 
serum diluted  in  EDTA;  NHS-Mg-EGTA, normal  human serum diluted  1:4 in  GVB-Mg-EGTA; P, 
properdin;  PBS  ++, phosphate-buffered saline containing 0.6 mM Ca  +÷ and 0.4 mM Mg++; Sepharose- 
CNBr, CNBr-activated Sepharose lacking heparin;  Sepharose-heparin, CNBr-activated Sepharose with 
coupled heparin; Zy, zymosan; Zy,C3b; C3b-bearing Zy particles; Zy-CNBr, CNBr-activated Zy particles 
lacking heparin; Zy-heparin, CNBr-aetivated Zy particles with coupled heparin. 
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cation eonvertase at  the C3b site  (26).  In addition, fllH displaces Bb, the catalytic 
unit,  from  any  amplification  convertase sites  that  may have  formed  (27,  28)  and 
augments  cleavage  inactivation  of particle-bound  C3b  by  C3bINA  (27,  29).  The 
inverse relationship between the membrane content of sialic acid and the capacity of 
the cell to activate the alternative pathway by deposition  and  maintenance  of the 
amplification convertase on the surface was established by demonstrating the effects 
of chemical modification (24)  or enzymatic removal (24, 25)  of this moiety on sheep 
erythrocytes,  and  was  confirmed  by  showing  the  same  relationship  with  natural, 
genetically determined variations of sialic acid on mouse erythrocytes (9). 
Although  the capacity to recognize a  relative deficiency of cell-surface sialic acid 
represents a mechanism by which the alternative pathway could lead to phagocytosis 
and cytolysis of a foreign cell in a nonimmune host, the failure of mammalian sera to 
lyse normal homologous cells indicates the existence of additional cell-surface constit- 
uents  that  modulate the capacity of a  particle to activate the alternative pathway. 
The proteoglycan, heparan sulfate, has been identified as a cell-surface constituent of 
cultured human fibroblasts (30)  and endothelial cells (31)  and of certain animal (32- 
35)  and  tumor  cells.  Heparin  resembles  heparan  sulfate  in  having  glucuronic  or 
iduronic acid in a  disaccharide pair with glucosamine. Heparin and heparan sulfate 
differ from chondroitin  sulfates, dermatan sulfate, and keratan sulfate in the nature 
of their glycosidic linkages and in being the only glycosaminoglycans with N-sulfation 
in addition  to O-sulfation, although  more glucosamine in heparin than  in heparan 
sulfate is N-sulfated rather than N-aeetylated (36, 37).  Because of the availability of 
heparin, the coupling of this glycosaminoglycan to an activating particle was assessed 
for its effect on the activating capacity of that particle. Coupled heparin glycosamino- 
glycan suppressed the capacity of zymosan to activate the human alternative pathway 
by a  dose-dependent  facilitation of the regulatory action of the endogenous control 
proteins, fllH and C3bINA, on particle-bound C3b. 
Materials and Methods 
Preparation of Heparin and of Zymosan-Heparin Particles.  400  mg of commercial heparin gly- 
eosaminoglycan  from  hog  intestine  (H-3125,  Sigma  Chemical  Co.,  St.  Louis,  Mo.)  were 
dissolved  in 4 ml of 0.01 M Tris HCI, pH 8.0, containing 1.0 M  NaCI and applied to a  1-  × 
30-era column of Dowex 1X2 (100-200  mesh, chloride form; Bio-Rad Laboratories, Richmond, 
Calif.)  equilibrated with the same buffer. The~  column was eluted in a stepwise  fashion with 
0.01 M Tris, pH 8.0, containing 1.0 M and 3.0 M NaC1 (38, 39). The heparin was recovered in 
the  3.0-M  NaC1  eluate,  dialyzed  against  10  volumes of distilled  H~D  for  18  h  at  room 
temperature, and concentrated to -50 mg/ml by dialysis against polyethylene glycol, tool wt 
20,000 (Fisher Scientific Co., Pittsburgh, Pa.) in a Speetrapor 1 membrane (Spectrum Medical 
Industries Inc., Los Angeles,  Calif.).  Heparin was assayed by metachromasia with azure A 
(Fisher Scientific Co.) (40, 41) with use of a reference curve established with commercial heparin 
that was linear between 10 and 100 #g/ml, and also by uronic-aeid content relative to a heparin 
standard with use of the carbazole reaction as modified by Bitter and Muir (42). 
Zymosan (Zy)  (Schwarz/Mann  Div.,  Becton,  Dickinson  & Co., Orangeburg,  N.  Y.)  was 
boiled for 45 rain at 0.15 M  NaC1, washed,  and stored as a 25-mg/ml suspension  in 0.15 M 
NaC1 at 2°C.  125 mg of Zy in 5 ml of 0.1  M NaHCO3, pH 8.5, were incubated with an equal 
volume of 0.1 M NaHCOs containing 90 mg of cyanogen bromide (CNBr)  for 10 min at 4°C, 
during which a  pH of 10.5 was maintained by addition of 2.5  M  NaOH  (43). The CNBr- 
activated Zy-particles were washed once in ice-cold distilled  H20 and three times in ice-cold 
0.1 M NaHCOa, resuspended in 5 ml of 0.1 M NaHCOa, and incubated with various amounts 
of heparin overnight  at  4°C  with  gentle stirring.  Unsubstituted  groups on the  Zy-heparin 1204  HEPARIN ON  ZYMOSAN  INHIBITS ALTERNATIVE  PATHWAY  ACTIVATION 
particles were  blocked  by  a  further  incubation  for  I  h  in  0.2  M  Tris,  pH  8.0,  at  room 
temperature. The Zy-heparin particles were then washed four times in 0,2 M  Tris, pH 8.0, and 
once in Veronal-buffered saline, pH 7.5 (VBS), containing 0.1% gelatin (GVB), adjusted to a 
concentration of 1 ×  109/ml in GVB with a  model 2F Coulter counter (Coulter Electronics 
Inc., Hialeah, Fla.) and stored at 2°C. CNBr-treated Zy particles lacking heparin (Zy-CNBr) 
were prepared in parallel. The amount of heparin on CNBr-activated Zy particles with coupled 
heparin  (Zy-heparin)  was  determined  by  hydrolytic release of the  glycosaminoglycan side 
chains with 0.5 M NaOH for 18 h at room temperature (41, 44) and quantitation of the heparin 
in the supernate after sedimentation of the particles. No metachromatic material was released 
from Zy-CNBr particles and the material registering in the uronic-acid assay (which approxi- 
mated 3.2 #g of uronic acid/109 particles) was subtracted for the calculation of heparin release 
from  Zy-heparin by the  uronic-acid assay. Approximately 1% of the  input  of heparin was 
coupled to CNBr-activated Zy, whereas no heparin was bound to Zy particles processed in the 
same manner. 
CNBr-activated  Sepharose  With  coupled  heparin  (Sepharose-heparin)  was  prepared  by 
incubating 20 mg of heparin with 3 ml of packed Sepharose 4B (Pharmacia Fine Chemicals, 
Div. of Pharmacia, Inc., Piscataway, N.J.) activated by 90 mg of CNBr (45), and the particles 
were then  processed as for the  preparation of Zy-heparin. To  prepare Zy particles bearing 
human transferrin or human serum albumin, 240/~g of transferrin or 150/tg of albumin were 
incubated with ~ 109 CNBr-activated Zy particles under the same conditions as for coupling 
heparin. The quantity of protein coupled was calculated from the decrease in protein content 
of the supernate after the coupling reaction. 
Enzymatic Removal of  Heparin  from the Zymosan-Heparin Particles.  Crude heparinase was prepared 
from Flavobacterium heparinum by the method of Linker and Hovingh (46);  the preparation had 
3 U  of heparinase/100 #1 and contained other mucopolysaccharidases, hut had no detectable 
proteolytic activity. 1 U  of enzyme is defined as the quantity that catalyzes the formation of 1 
~mol of unsaturated uronides per h at 37°C from a heparin substrate. Zy-heparin particles, 2 
×  l0  s,  in phosphate-buffered saline containing 0.6 mM Ca  ++, and 0.4 mM Mg  ++  (PBS  ++) 
were incubated with 0.055-1.5 U of heparinase at 37°C for designated intervals. The particles 
were washed twice in PBS ++, twice in GVB, and examined for residual heparin. Zy-heparin 
particles, 2  ×  10  s, were also incubated with 6 U of chondroitin ABC lyase (Miles Laboratories 
Inc., Miles Research Products, Elkhart, Ind.) (1 U of enzyme catalyzes the formation of 1/~mol 
of product per h) in 0.25 M  NaCI, 0.17 M  Na acetate, and 0.2 M  Tris HCI, pH 8.0, containing 
50 mg/ml bovine serum albumin for 1 h at 37°C. Under these conditions, 6 U  of chondroitin 
ABC lyase degraded 25/~g each of a mixture containing equal amounts of chondroitin 4-sulfate, 
chondroitin 6-sulfate, and dermatan sulfate, as assessed by gel filtration of the mucopolysac- 
charides before and after degradation (47, 48). 
Assays and Preparation of Alternative Pathway Proteins.  B (49), C3 (50), P (23), [) (21), ,B 1H (28), 
and C3bINA (51) were purified to homogeneity as assessed by polyacrylamide gel electropho- 
resis of their reduced forms in the presence of sodium dodeeyl sulfate (52). C3 and B hemolytic 
activities were assayed as described (53,  54).  C3 was trace labeled with  125I (New England 
Nuclear, Boston, Mass.) by use of insoluble lactoperoxidase (Worthington Biochemical Corp., 
Freehold, N. J.)  (55)  to asp  act of 85,000 cpm//xg without  loss of functional activity. GVB 
containing 0.15  mM  calcium and  0.5  mM  magnesium  (GVB÷+), half-isotonic GVB ÷+ with 
2.5%  dextrose  (DGVB++),  GVB  containing 0.04  M  EDTA  (GVB-EDTA)  (56),  and  GVB 
containing 2  mM  magnesium  and  8  mM  EGTA  (GVB-Mg-EGTA)  (57)  were  prepared as 
described. 
Activation of the alternative pathway by Zy particles was examined by measuring inacti- 
vation of B and C3 in normal serum which had been diluted in GVB-Mg-EGTA to prevent 
classical pathway activation (57, 58). 2.5  ×  10  r particles were suspended in 0.025 ml of 0.15 M 
NaC1 and added to 0.2 ml of normal human serum diluted 1:4 in GVB-Mg-EGTA (NHS-Mg- 
EGTA). The reaction mixtures were incubated with agitation at 37°C, during which duplicate 
0.01-ml samples were removed at timed intervals and added to either 1 ml of ice-cold DGVB ++ 
or GVB containing 5 mM EDTA for subsequent assay of residual C3 or B hemolytic activity. 
To assess the function of particle-bound C3b, particles were prepared (23) by incubation of 
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respectively, with 105 #g of unlabeled  or 125I-labeled C3, 50 #g of B, and 0.05 #g of I5 in GVB 
containing 1.5 mM Mg  ++ for 1 h at 30°C. The particles were washed twice in EDTA and once 
in GVB  +÷. The number of 125I-C3b molecules bound per particle was 520 for Zy, 1,320 for Zy- 
CNBr,  and  1,520 for Zy-heparin.  Zy,C3b,  Zy-CNBr,C3b,  and Zy-heparin,C3b  particles  were 
incubated with 0.15 #g of B and 0.05 #g of D in 0.2 ml of GVB  ++ containing 1.5 mM Mg  ++ at 
37°C.  At timed  intervals,  0.01-ml samples were  removed,  added  to 0.2  ml  of GVB  ++, and 
centrifuged for 2 min at 1,300  g; the supernates  were assayed for residual B hemolytic activity. 
Nonspecific adsorption  of B to the particles was assessed in parallel reaction mixtures in which 
B was incubated with the particles in the absence of 15 or in GVB-EDTA in the presence of I~ 
and this figure was subtracted,from  the B input to permit calculation  of specific B inactivation. 
The percentage  of C3b-dependent  inactivation  of B for each  type of particle  was directly 
related  to the input of particle-bound C3b. 
Results 
Inhibition by Surface-bound Heparin of Zymosan-induced Activation of the Alternative Pathway 
in Normal Human Serum.  The relative capacity of Zy, of Zy-CNBr, and Zy-heparin 
particles, prepared in a ratio of 29 mg of heparin to ~ 109 CNBr-activated Zy particles, 
to  activate  the  alternative  pathway was  compared  in  NHS-Mg-EGTA. B  and  C3 
inactivation by Zy and  Zy-CNBr increased  progressively throughout the period of 
observation and exceeded 50% after 30 min. In contrast, Zy-heparin had no capacity 
to activate the  alternative  pathway as  B  and  C3 consumption was limited  to that 
observed in the absence of particles (Fig.  1). 
Zy-heparin particles bearing different amounts of heparin were compared for their 
capacity to inactivate B  in  NHS-Mg-EGTA during a  45-min  incubation.  The Zy- 
CNBr particles  that had not been incubated with heparin inactivated 90% of the B 
activity. The amount of heparin present in the initial coupling reaction or bound to 
the particle was inversely related to the capacity of Zy-heparin to inactivate B  (Fig. 
2).  The correlation between B inactivation and the amount of heparin bound (r  = 
0.97, P <0.01)  is such that complete inhibition of activating capacity, as calculated 
by linear regression, would be achieved by 11.5 x  106 molecules/particle. 
The coupling of 1.1  ×  106 molecules of human transferrin or 0.9  ×  106 molecules 
of human serum albumin/particle to Zy-CNBr did not alter the capacity of particles 
to  inactivate  B  and  C3  in  NHS-Mg-EGTA.  When  the  particles  bore  8.3  X  106 
molecules of heparin,  which  represents  a  weight equivalent  to that  of the coupled 
proteins,  the inactivation of B was reduced from 82 to  13%, and of C3 from  78 to 
15%. Treatment  of a  replicate  portion of Zy-heparin with  1.5  U  of heparinase/0.2 
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FI~.  1.  Time  course of inactivation of B (A) and C3 (B) in NHS-Mg-EGTA  induced by zymosan 
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FIo,  2.  Dose-response relationship between the amount ofheparin in the coupling reaction (&) or 
the amount of heparin bound to zymosan and the capacity of the particles to induce B inactivation 
in NHS-Mg-EGTA.  Particle-bound  heparin was assessed either by metachromatic (0)  or uronic 
acid (O) assay. 
×  109 particles for 2 h  restored their B and C3 inactivating capacity to that of the 
original Zy-CNBr, whereas treatment with 6 U  of chondroitin ABC lyase/0.2  ×  109 
particles had no effect. 
To assess whether limited treatment with heparinase of a nonactivating Zy-heparin 
particle would yield particles with incremental activating capacities, 0.2  ×  109 Zy- 
heparin particles (13.1  ×  106 molecules ofheparin/particle) were treated with 0.06 or 
0.3 U of heparinase for 5, I0, 20, or 30 min at 37°C, and the residual heparin on each 
batch was assessed.  There was a  significant inverse correlation (r  --  0.98, P  <0.01) 
between  the  residual  bound  heparin  and  the  relative capacity of the  particles  to 
induce B inactivation in NHS-Mg-EGTA after a 45-min interaction (Fig. 3). Complete 
inhibition of the activating capacity of Zy requires 12.9  ×  106 molecules of heparin/ 
particle, as calculated by linear regression; this number is similar to that  observed 
when bound heparin was varied based upon its concentration in the coupling step 
(Fig. 2). 
The inhibitory effect of surface-bound heparin on the capacity of another alterna- 
tive pathway-activating particle to induce B and (23 consumption in NHS-Mg-EGTA 
was  examined  with  (2NBr-activated  Sepharose  lacking  heparin  (Sepharose-CNBr) 
and Sepharose-heparin before and after treatment with 1.5 U of heparinase/0.2 ml of 
packed beads  for 2 h  at  37°(2.  70%  (vol/vol) Sepharose-(2NBr, Sepharose-heparin, 
heparinase-treated Sepharose-(2NBr, and heparinase-treated Sepharose-heparin in 0.2 
ml  of GVB  were  incubated  with  0.25  ml  of NHS-Mg-EGTA,  and  samples  were 
assessed for residual (73 and B function after 0-, 5-,  15-, 30-, and 45-min incubations 
at 37°C. Sepharose-(2NBr, whether or not treated with heparinase, induced progres- 
sive  B  and  C3  consumption  that  reached  70  and  52%,  respectively,  at  45  rain. 
Sepharose-heparin had no capacity to activate the alternative pathway, as B and C3 
consumptions were limited to that observed in the absence of particles, namely, 2 and 
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vating  capacity  to  that  observed  with  Sepharose-CNBr,  thereby  confirming  the 
inhibitory effect of the coupled glycosaminoglycan on a  second activating particle. 
Augmentation by  Surface-bound Heparin of Inactivation of Bound C3b  by  C3bINA and 
fllH.  The  inhibitory  effect of coupled  heparin  on  the  capacity  of a  particle  to 
activate  the  human  alternative pathway  could  be  a  result  of the  failure of such 
particles to accept C3b  from the fluid phase, of the impaired  function of particle- 
bound C3b, or of augmented inactivation of particle-bound C3b by the regulatory 
proteins. The formation of C3b-bearing particles by a  fluid phase reaction mixture 
containing l~SI-labeled  C3,  as  described in  Materials  and  Methods,  did  not  reveal 
impaired  uptake  of C3b  in  the  presence of bound  heparin.  Numbers  of particles 
bearing equivalent amounts of C3b, namely, 2  ×  107 Zy-heparin,C3b, 2.3  ×  10?Zy  - 
CNBr,C3b, and 5.6 ×  107 Zy,C3b, inactivated B in the presence of D  as a first order 
reaction (Fig. 4). Furthermore, B consumption by Zy-heparin,C3b equaled that  by 
Zy-CNBr,C3b and exceeded that by Zy,C3b, thereby indicating that heparin did not 
impair the function of particle-bound C3b. 
The relative susceptibility of bound C3b to inactivation either by purified control 
proteins  or  by  normal  human  serum  diluted  in  GVB-EDTA  (NHS-EDTA)  was 
studied  in  kinetic  experiments.  Amounts  of  Zy,C3b,  Zy-CNBr,C3b,  and  Zy- 
heparin,C3b (17.6  ×  10  e molecules of heparin/particle) were selected to give a range 
of 50-65% B inactivation in the presence of l~ in 60 min at 37°C when the particles 
were not pretreated with either source of control proteins. Four samples each of 4  × 
107  Zy,C3b,  1.5  ×  t07  Zy-CNBr,C3b,  1  X  107  Zy-heparin,C3b,  and  4  X  107 
EAC4b,3b  in  0.1  ml  GVB  ÷+  were  incubated  at  37°C  for  60  min,  during  which 
replicates of each particle type received 0.1 ml of a  1:25 dilution of NHS-EDTA at 0, 
15,  30,  and  45  min,  respectively.  Additional  samples  of each  particle  type  were 
incubated with buffer alone for 60 min at 37°C. All reactions were stopped by the 
addition of 1 ml of ice-cold GVB  ÷+ and washing of the particles at 4°12. Particles that 1208  HEPARIN  ON  ZYMOSAN  INHIBITS  ALTERNATIVE  PATHWAY  ACTIVATION 
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FIo.  4.  Rate of inactivation of the hemolytic activity of B by Zy C3b (0), Zy-CNBr,C3b (O) and 
Zy-heparin,C3b (A) in the presence of I) and Mg  ÷+. 
had  been  incubated  in  buffer alone were  defined  as  having  100%  of bound  C3b 
activity as assessed by inactivation of B in the presence of I7). C3b on Zy or on Zy- 
CNBr was relatively resistant to inactivation by control proteins in NHS-EDTA with 
only 50% loss of function after 60 min. The activity of C3b on Zy-heparin was reduced 
by >90%, with the rate of inactivation resembling that of C3b on sheep erythrocytes, 
a nonactivating particle of the human alternative pathway (Fig. 5 A). The experiment 
was repeated by treating the same four sets of particles with 2 #g of C3bINA and  18 
#g of fllH in 0.1  ml EDTA. C3b was rapidly inactivated on sheep erythrocytes and 
Zy-heparin, whereas C3b on Zy or Zy-CNBr was again relatively resistant to inacti- 
vation by control proteins (Fig. 5 B). 
The effect of particle-bound heparin on the inactivation of bound C3b by C3bINA 
was examined for the importance of flirt as a  cofactor. 3  X  107 Zy-CNBr,C3b and 
Zy-heparin,C3b (13.1  X  10  6 molecules of heparin/particle) were each incubated with 
2 #g of C3bINA in the presence and absence of 18 #g offllH, or with buffer alone. 
Particles  incubated  in  buffer  alone  were  defined  as  having  100%  of bound  C3b 
activity. C3bINA  alone inactivated  10 and  15% of the C3b  on  Zy-CNBr and  Zy- 
heparin, respectively, by 60 rain. In the presence of ill H, the inactivation of C3b was 
increased to 55% on Zy-CNBr and to 99% on Zy-heparin, emphasizing that  bound 
heparin augments the cofactor role of fl I H  (Fig. 6). 
When the same particles were treated with heparinase at a  ratio of 1.5 U  per 0.2 
×  109 Zy-CNBr,C3b or Zy-heparin,C3b, there was  no loss of C3b function. Before 
and  after  heparinase  treatment,  Zy-heparin,C3b  inactivated  67%  and  63%  of B, 
respectively, in the presence of [). Similarly, Zy-CNBr,C3b inactivated 59% and 66% 
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FIG.  5.  Time course of inactivation of C3b bound to Zy (O), Zy-CNBr (O), Zy-heparin (&), and 
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FIo.  6.  Time course of inactivation of C3b bound to Zy-CNBr (0, O) and to Zy-heparin (A, A) 
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of~lH (solid line). 
and Zy-heparin,C3b with or without prior heparinase treatment were incubated with 
2 #g of C3bINA and  18 #g offllH  for timed intervals and then assessed for residual 
particle-bound C3b activity. C3b on Zy-heparin particles without heparinase pretreat- 1210  HEPARIN  ON  ZYMOSAN  INHIBITS  ALTERNATIVE  PATHWAY  ACTIVATION 
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Fro.  7.  Correlation  between  the  number  of  molecules  of heparin/zymosan  particle  and  the 
percentage of residual C3b activity on the particles after treatment with purified C3bINA and fllH. 
ment was  100% inactivated by the purified control proteins in 30 min; C3b on the 
heparinase-treated Zy-heparin particles had regained resistance comparable to that 
of C3b on Zy-CNBr particles pretreated with buffer or heparinase, in that only 60% 
of the C3b was inactivated at 60 min. 
Some of the particles described in Fig.  3  in  terms of their heparin content and 
alternative pathway-activating capacity were converted to C3b-bearing intermediates 
in  order  to  examine  the  dose-response  effects  of particle-bound  heparin  on  the 
regulatory function of C3bINA and fllH. 2 ×  107 Zy-heparin,C3b bearing 2.64, 4.48, 
7.28, or  13.1  X  106 molecules of heparin/particle and 2  ×  10  7 Zy-CNBr,C3b were 
treated with 2/~g of C3bINA and 18 btg offllH for 45 min and each particle type was 
assayed for residual C3b activity. The capacities of untreated particles to induce B 
inactivation in the presence of I) were comparable and defined as 100% C3b activity 
for each particle type. Residual C3b activity was inversely correlated to the number 
of molecules of heparin/particle  (r  =  0.99,  P  <0.01)  (Fig.  7),  indicating that  the 
susceptibility  of particle-bound  C3b  to  the  inactivation  by  the  purified  control 
proteins increased with the amount of heparin bound/particle. 
Discussion 
Discrimination by the alternative pathway between activating and nonactivating 
particles Or cells occurs after C3b  deposition and  is  related to  the modulation by 
surface constituents of the interaction of C3b  with the control proteins, fllH, and 
C3bINA (22, 23). The relative amount of membrane sialic acid is inversely related to 
the  relative  capacity  of sheep  or  mouse  erythrocytes  to  activate  the  alternative 
complement pathway in whole human serum (9, 24). Membrane-associated sialic acid 
promotes high-affinity binding offl  1H to cell-bound C3b without altering the binding 
of B to C3b (26), thereby impairing formation of C3b,Bb, facilitating extrinsic decay 
of any C3b,Bb already generated, and enhancing inactivation of C3b by C3bINA. In 
an analogous manner, the amount of heparin coupled to the surface of Zy particles is 
inversely related to the capacity of the particles to activate the alternative complement 
pathway  because  coupled  heparin  augments  the  regulatory  action  of fllH  and 
C3bINA on particle-bound C3b. 
Heparin glycosaminoglycan coupled to Zy impaired in a  dose-dependent manner 
the ability of the particle to activate the alternative pathway as assessed by inactivation 
of B and C3 in NHS-Mg-EGTA. The suppressive effect of coupled heparin on the M. KAZATCHKINE, D. FEARON, J. SILBERT, AND K. AUSTEN  1211 
activating function of Zy-CNBr was not duplicated by coupling transferrin or serum 
albumin, and was not reversed by treating the Zy-heparin particles with chondroitin 
ABC lyase. The ability of bound heparin to impair the alternative pathway-activating 
capacity of the carrier  particle was  not  peculiar to  Zy but  was  also  observed  in 
comparable experiments with Sepharose.  The loss of alternative pathway-activating 
capacity was significantly  correlated (P <0.01)  to the number of molecules of heparin 
bound/Zy particle  when  the  ratio  was  adjusted either by  varing the  amount of 
heparin in the initial coupling reaction (Fig. 2) or by enzymatically removing graded 
amounts of heparin from a fully inhibited Zy-heparin particle (Fig. 3). Analysis by 
linear regression  of the effect of each method of adjusting the amount of heparin/ 
particle showed that complete inhibition of activating capacity would be achieved by 
the presence of at least  11.5 ×  106 (Fig. 2) or 12.9 ×  108 (Fig. 3) molecules ofheparin/ 
particle. 
The inhibition by coupled heparin of the capacity of a  particle to activate the 
human  alternative pathway could  have  been  secondary to  the  inability of such 
particles to bind C3b from the fluid phase, to the impaired interaction of particle- 
bound C3b  with B and I~ to form the amplification convertase, or to augmented 
inactivation of particle-bound C3b by the regulatory proteins. There was equivalent 
uptake of radiolabeled C3 by Zy-CNBr, a particle retaining activating capacity, and 
by Zy-heparin during the fluid phase  interaction of C3,  B, and  15.  Further, C3b 
bound to Zy-heparin has the same capacity as C3b bound to Zy-CNBr to interact 
with B to permit its cleavage by I) (Fig. 4), thereby indicating unimpaired function 
of C3b on Zy-heparin in the absence of control proteins. In contrast to surface-bound 
heparin, fluid-phase heparin directly interferes with the ability of C3b bound to a 
nonactivating particle to form C3b,Bb (59). The presence  of heparin on Zy did not 
alter binding or function of C3b, excluding these reactions as the sites of inhibition by 
surface-bound heparin of alternative pathway activation. 
The effect of heparin coupled to Zy was to augment inactivation of bound C3b by 
the regulatory proteins  to an extent comparable to the inactivation of C3b  on a 
nonactivating cell,  the  sheep  erythrocyte. Although human serum  chelated  with 
EDTA or the combination of purified C3bINA and fllH were relatively ineffective in 
removing C3b function from Zy or Zy-CNBr, particles which activate the alternative 
pathway, the control proteins rapidly inactivated C3b on nonactivating particles such 
as sheep erythrocytes or Zy-heparin (Figs. 5A and B). The absence offllH from the 
purified control protein mixture resulted in almost no inactivation of C3b presented 
as  either Zy-CNBr,C3b or Zy-heparin,C3b, thereby indicating that surface-bound 
heparin facilitates the cofactor role offllH for C3bINA by promoting the interaction 
between fllH and bound C3b (Fig. 6). 
Increasing amounts of heparin on the Zy surface were significantly correlated (P 
<0.01)  with increased numbers of C3b sites that were susceptible  to inactivation by 
C3bINA  in  the  presence  of fllH  (Fig.  7).  By  linear  regression  analysis  of this 
correlation,  the  number  of heparin  molecules/particle required  to  promote  total 
inactivation of bound C3b by purified control proteins was estimated to be  13.8 × 
106, which corresponds  to the amount of heparin required to abolish the activating 
capacity of Zy in NHS-Mg-EGTA (Figs. 2 and 3).  This finding suggests  that the 
augmentation of endogenous regulation by bound-heparin is responsible  for the loss 
of activating capacity by Zy-heparin particles in serum. 1212  HEPARIN  ON  ZYMOSAN  INHIBITS  ALTERNATIVE  PATHWAY  ACTIVATION 
Initial studies of specific cell-surface biochemical characteristics that  modulated 
recognition by the alternative pathway involved the conversion of a  nonactivating 
cell, the sheep erythrocyte, into an activating cell by removal of sialic acid residues 
(24, 25). In the studies presented here, an activating particle, Zy, is transformed into 
a nonactivating particle by the coupling to its surface of heparin glycosaminoglycan. 
Although structurally dissimilar,  both  sialic acid  and  heparin  glycosaminoglycan, 
when on  a  surface of a  particle,  promote the  interaction of bound C3b  with  the 
regulatory proteins, fllH  and  C3bINA,  to  prevent  formation and  function of the 
bound amplification convertase, C3b,Bb. Because heparin and heparan sulfate mol- 
ecules can be specifically bound to nucleated cells (60, 61) and because nucleated cells 
in  culture  bear  heparin-related  polysaccharides  (30-35),  heparin-related  sulfated 
mucopolysaccharides may modulate  the  activation of the  alternative pathway by 
some mammalian cells. 
Summary 
Discrimination by the human alternative pathway between activating and nonac- 
tivating particles occurs after deposition of C3b by the continuous low-grade inter- 
action of the alternative pathway components in biologic fluids and is dependent on 
the modulation by surface constituents of the interaction of bound C3b  with the 
control proteins, fllH, and C3b inactivator (C3bINA). When heparin glycosamino- 
glycan was coupled to activating particles, such as zymosan or Sepharose, by cyanogen 
bromide activation, their capacity to activate the human alternative pathway was 
inhibited. The loss of alternative pathway-activating capacity was directly correlated 
to the number of heparin molecules bound/zymosan particle, whether the ratio was 
varied by increasing the amounts of heparin in the initial coupling reactions or by 
treating  a  fully inhibited  particle  with  incremental  concentrations of heparinase. 
Analysis by linear regression of the inhibitory effect of each procedure  (r  --  0.97,  r 
-- 0.98, respectively) for adjusting the number of heparin molecules/particle revealed 
that  the  dose-response  relationships  were  identical  and  that  complete  inhibition 
occurred with >12  X  106 molecules of heparin/zymosan particle.  The coupling of 
heparin to zymosan did not impair the uptake of C3b from the fluid-phase interaction 
of C3, B, and I~, and did not alter the capacity of bound C3b to associate with B so 
as to permit its inactivation by D. Although the regulatory proteins present in normal 
serum chelated with EDTA or presented as a combination of purified C3bINA and 
fllH were relatively inefficient in inactivating C3b function on an activating particle 
of the  alternative  pathway  such  as  zymosan  or  zymosan-cyanogen bromide,  the 
control proteins rapidly inactivated C3b on a nonactivating particle such as a sheep 
erythrocyte or zymosan with coupled heparin. The increased numbers of C3b sites 
susceptible  to  inactivation by C3bINA  in  the presence  of fllH  were  significantly 
correlated to the number of molecules of heparin/particle. By linear regression analysis 
of the correlation (r  =  0.99)  the number of heparin molecules/particle required to 
promote total inactivation of bound C3b by purified control proteins was 13.8 ×  106. 
This molecular analysis suggests that the action of heparin coupled to an activating 
particle of the alternative pathway is to promote the interaction between particle- 
bound C3b and the regulatory proteins, thereby preventing particle-associated am- 
plified C3 cleavage. It is noteworthy that both surface constituents known to maintain M.  KAZATCHKINE, D.  FEARON, J.  SILBERT,  AND K.  AUSTEN  1213 
a  particle  as  a  nonactivator  of the  alternative  pathway,  sialic  acid  and  N-sulfated 
mucopolysaccharide, act by facilitating the inactivation by regulatory proteins of the 
function of particle-bound C3b. 
Received  for publication 9July 1979. 
References 
1.  Wardlaw,  A.  C., and  L.  Pillemer.  1956. The properdin  system and  immunity.  V.  The 
bactericidal activity of the properdin system. J. Exp. Med. 103:553. 
2.  Gewurz, H., H.  S.  Shin, and  S,  E,  Mergenhagen.  1968. Interactions of the complement 
system with endotoxic lipopolysaccharide: consumption of each of the six terminal comple- 
ment components.J. Exp. Med. 128:1049. 
3.  Winkelstein,  J.  A.,  H.  S.  Shin,  and  W.  B.  Wood, Jr.  1972. Heat  labile  opsonins  to 
pneumococcus. III. The participation of immunoglobulin and of the alternative pathway 
of (23 activation. J. Immunol. 198:1681. 
4.  Schreiber,  R.  D.,  D.  (2.  Morrison,  E.  R.  Podack,  and  H.  J.  Mfiller-Eberhard.  1979. 
Bactericidal  activity of the alternative complement pathway generated from  11  isolated 
plasma proteins.J.  Exp. Med. 149:870. 
5.  Macher, A. M., J. E. Bennett, J. E. Gadek, and M. M. Frank.  1978. Complement depletion 
in cryptococcal sepsis.J.  Immunol. 120:1686. 
6.  Pillemer, L., L. Blum, I. H. Lepow, O. A. Ross, E. W. Todd, and A. C. Wardlaw.  1954. 
The  properdin  system and  immunity.  I.  Demonstration  and  isolation  of a  new  serum 
protein, properdin, and its role in immune phenomena. Science (Wash. D. C.).  120:279. 
7.  Kierzenbaum, F.,  and D. Weinman.  1977. Antibody-independent activation of the alter- 
native complement pathway in human serum by parasitic cells. Immunology. 32:245. 
8.  Platts-Mills,  T.  A.  E., and  K.  Ishizaka.  1974.  Activation of the alternative  pathway of 
human complement by rabbit cells. J. Immunol. 113:348. 
9.  Nydegger, U. E., D. T. Fearon, and K  F. Austen.  1978. Autosomal locus regulates inverse 
relationship  between  sialic  acid content  and  capacity of mouse erythrocytes to activate 
human alternlative  complement pathway. Proc. Natl. Acad. Sci. U. S. A. 75:6078. 
10.  Eidinger,  D., E.  Beilo,  and  A.  Mates.  1977. The heterocytotoxicity of human serum.  I. 
Activation  of the  alternative  complement  pathway  by  heterologous  target  cells.  Cell. 
Immunol. 29:.  174. 
11.  Okada, H., N. Okada, and H. Shibuta.  1979. (2omplement activating ability induced on 
cell membrane by Sendai virus injection. Fed. Proc. 38:1217. 
12.  Sissons, J. G. P., M. B. A. Oldstone, and R. D. Schreiber.  1979. Lysis of virus infected cells 
by antibody and isolated proteins of the cytolytic alternative pathway. Fed. Proc. 38:1216. 
13.  Theophilopoulos, A. N., and L. H. Perrin.  1977. Lysis of human cultured lymphoblastoid 
cells by cell induced activation of the properdin pathway. Science (Wash. D.  C).  195:878. 
14.  Budzko, D.  B.,  P. J.  Lachmann, and I. McConnell.  1976. Activation of the alternative 
complement pathway by lymphoblastoid cell  lines  derived  from patients  with  Burkitt's 
lymphoma and infectious mononucleosis. Cell. Immunol. 22:98. 
15.  Fearon,  D.  T.,  and  K.  F.  Austen.  1975. Initiation  of (23  cleavage  in  the  alternative 
complement pathway. J. Immunol. 115:1357. 
16.  Fearon, D. T., and K.  F. Austen.  1975. Properdin.  Initiation of alternative complement 
pathway. Proc. Natl. Acad. Sci. U. S. A. 72:3220. 
17.  Law, S. K., and R. P. Levine. 1977. Interaction between the third complement protein and 
cell surface macromolecules. Proc. Natl. Acad. ScL  U. S. A.  174:2701. 
18.  Vogt, W., W. Dames, G. Schmidt, and L. Dieminger. 1977. (2omplement activation by the 
properdin system: formation of a stoichiometric (23 cleaving complex of properdin factor 1214  HEPARIN ON  ZYMOSAN  INHIBITS ALTERNATIVE PATHWAY ACTIVATION 
B with C3b. Immunochemistry.  14:201. 
19.  Mfiller-Eberhard, H. J., and O. Gotze.  1972. C3 proactivator convertase and its mode of 
action. J. Exp.  Med.  135:1003. 
20.  Fearon, D. T.,  K.  F. Austen, and  S.  Ruddy.  1973. Formation of a  hemolytically active 
cellular intermediate  by  the  interaction  between  properdin  factors  B  and  D  and  the 
activated third component of complement. J. Exp. Med.  138:1305. 
21.  Fearon, D. T., and K. F. Austen. 1975. Properdin: binding to C3b and stabilization of the 
C3h-dependent C3 convertase.J. Exp. Med.  142:856. 
22.  Fearon, D. T., and K. F. Austen. 1977. Activation of the alternative complement pathway 
with rabbit erythrocytes by circumvention of the regulatory action of endogenous control 
proteins.J. Exp. Med.  146:22. 
23.  Fearon, D. T., and K. F. Austen. 1977. Activation of the alternative complement pathway 
due to resistance of zymosan bound  amplification convertase to endogenous regulatory 
mechanisms. Proc. Natl. Acad.  Sci.  U. S. A.  74:1683. 
24.  Fearon, D. T. 1978. Regulation by membrane sialic acid of  flirt-dependent decay-dissocia- 
tion of the amplification C3 convertase of the alternative complement pathway. Proc. Natl. 
Acad,  Sci.  U. S. A.  75:1971. 
25.  Pangburn,  M.  K,,  and  H. J.  MiJller-Eberhard.  1978. Complement  C3  convertase:  cell 
surface restriction of fllH control and generation of restriction on neuraminidase-treated 
cells. Proc. Natl. Acad.  Sci.  U. S. A.  75:2416. 
26.  Kazatchkine, M. D., D. T. Fearon, and K. F. Austen. 1979. Human alternative complement 
pathway: membrane-associated sialic acid regulates the competition between B and fllH 
for cell,bound C3b. J. Immunol.  122"75. 
27.  Whaley, K., and S. Ruddy. 1976. Modulation of the alternative complement pathway by 
fllH globulin.J. Exp. Med.  144:1147. 
28.  Weiler, J.  M.,  M.  R.  Daha,  K.  F.  Austen,  and  D.  T.  Fearon.  1976. Control  of the 
amplification convertase of complement by the plasma protein fllH. Proc. Natl. Acad.  Sci. 
U. S. A. 73:3268. 
29.  Pangburn, M. K., R. D. Schreiber, and H. J. Miiller-Eberhard. 1977. Human complement 
C3b inactivator: isolation, characterization, and demonstration of an absolute requirement 
for the serum protein, fllH, for cleavage of C3b and C4b in solution.J. Exp. Med.  146:257. 
30.  Kleinman, H. K., J. E. Silbert, and C. K. Silbert. 1975. Heparan sulfate of skin fibroblasts 
grown in culture. Connect. Tissue Res.  4:17. 
31.  Buonassisi, V., and M. Root.  1975. Enzymatic degradation of heparin-related mucopoly- 
saccharides from the surface of endothelial cell cultures. Biochim.  Biophys.  Acta. 385:1. 
32.  Dietrich, C. P., and H. M. De Oca.  1970. Production of heparin related mucopolysaccha- 
rides by mammalian cells in culture. Proc. Soc. Exp. Biol. Med.  134:955. 
33.  Kraemer, P. M.  1971. Heparan sulfates of cultured cells. II. Acid soluble and precipitable 
species of different cell lines. Biochemistry.  10:1445. 
34.  Winterbourne,  D. J.,  and  P. T.  Mora.  1978.  Altered metabolism of heparan sulfate in 
Simian virus 40 transformed cloned mouse eells.J. Biol.  Chem. 253:5109. 
35.  Underhill, C.  B., and J.  M.  Keller.  1975. A  transformation-dependent difference in the 
heparan sulfate associated with the cell surface. Biochem.  Biophys.  Res.  Commun. 63:448. 
36.  Taylor,  R.  L.,  Y.  E.  Shively,  H.  E.  Conrad,  and  J.  A.  Cifonelli.  1973. Uronic  acid 
composition of heparin and heparan sulfates. Biochemistry.  12:3633. 
37.  Lindahl, U.,  and  M.  Hook.  1978. Glycosaminoglycans and  their binding to biological 
macromolecules. Annu.  Rev.  Biochem.  47:385. 
38.  Schiller, S., G.  A.  Slover, and  A.  Dorfman.  1961. A  method  for the separation of acid 
mucopolysaccharides: its application to the isolation of heparin from the skin of rats. J. 
Biol.  Chem. 236:983. 
39.  Yurt, R. W., R. W. Leid, K. F. Austen, and J. E. Silbert. 1977. Native heparin from rat 
peritoneal mast cells.J. Biol.  Chem. 252:518. M.  KAZATCHKINE, D.  FEARON, J.  SILBERT,  AND  K.  AUSTEN  1215 
40.  Jaques, L. B., F. C. Monkhouse, and M. Stewart.  1949. A method for the determination of 
heparin in blood.J. Physiol. (Paris).  109.41. 
41.  Yurt,  R.  W., R.  W. Leid, J.  Spragg, and  K. F. Austen.  1977. Immunological release of 
heparin from purified rat peritoneal mast cells. J. Immunol. 118:1201. 
42.  Bitter, T., and H. Muir.  1962. A modified uronic acid carbazole reaction. Anal. Biochem. 4: 
330. 
43.  Axen, R., J. Porath, and S. Ernback.  I967. Chemical coupling of peptides and proteins to 
polysaecharides by means of cyanogen halides. Nature (Lond.).  214: t302. 
44.  Robinson, H. C., A. A. Homer, M. Hook, S. Ogren, and U. Lindahl.  1978. A proteoglycan 
form of heparin and its degradation to single-chain molecules. J. Biol. Chem. 253:6687. 
45.  Iverius, P. H.  1971. Coupling of glycosaminoglycans to agarose beads. Biochem.  J.  124:677. 
46.  Linker,  A.  L., and  P.  Hovingh.  1972. Heparinase  and  heparitinase  from Flavobacteria. 
Methods Enzymol. 28:902. 
47.  Yamagata, T., H. Saito, O. Habuchi, and S. Suzuki.  1968. Purification and properties of 
bacterial ehondroitinase and chondrosulfatases. J. BioL Chem. 243:1523. 
48.  Metcalfe,  D.  D.,  S.  I. Wasserman,  and  K.  F.  Austen.  Isolation and  characterization  of 
sulfated  mucopolysaecharides from  rat  basophil  leukemia  (RBL-1)  cells.  Biochem. J.  In 
press. 
49.  Hunsieker,  L. G.,  S.  Ruddy, and  K.  F.  Austen.  1973. Alternate  complement  pathway: 
factors  involved  in  cobra  venom  factor  (CoVF)  activation  of the  third  component  of 
complement (C3). J. Immunol. 110:128. 
50.  Tack, B. B., and J. W. Prahl.  1976. Third component of human complement: purification 
from plasma and physicochemical characterization. Biochemistry. 15:4513. 
51.  Fearon, D. T.  1977. Purification  of C3b inactivator and  demonstration  of its  two poly- 
peptide chain structure. J. ImmunoL 119:1248. 
52.  Weber, K., and M. Osborn.  1969. The reliability of molecular weight determinations by 
dodeeyl sulfate-polyacrylamide gel electrophoresis.J.  Biol. Chem. 244:4406. 
53.  Fearon, D. T., M. R. Daha, T. B. Strom, J. M. Weiler, C. B. Carpenter, and K. F. Austen. 
1977.  Pathways of complement activation  in membranoproliferative  glomerulonephritis 
and allograft rejection.  Transplant. Proc. 9:729. 
54.  Ruddy, S., and K. F. Austen.  1971. C3b inactivator of man. II. Fragments produced by 
C3h inactivator cleavage of cell bound or fluid phase C3b. J. Immunol. 107: 742. 
55.  Thorell, J., and I. Larsson.  1974. Lactoperoxidase coupled to polyacrylamide for radioio- 
dination of proteins to high specific activity. Immunochemist~y. 11:203. 
56.  Nelson,  R.  A., J.  Jensen,  I.  Gigli,  and  N.  Tamura.  1966. Methods  for the  separation, 
purification and measurement of the nine components of hemolytic complement in guinea 
pig serum. Immunochemisto~. 3:111. 
57.  Nydegger, U. E., D. T. Fearon, and K. F. Austen. 1978. The modulation of the alternative 
pathway of complement in C2 deficient human serum by changes in concentration of the 
component and control proteins.J. Immunol. 120:1404. 
58.  Bryant, R. E., and D. E. Jenkins, Jr. 1968. Calcium requirements for complement dependent 
hemolytic reactions.J. Immunol. 101:664. 
59.  Weiler, J.  M.,  R.  W.  Yurt,  D.  T.  Fearon, and  K.  F.  Austen.  1978. Modulation  of the 
formation of the amplification convertase of complement, C3b,Bb, by native and commer- 
cial heparin.J.  Exp.  Med.  147:409. 
60.  Kjellen, L., A. Oldberg, K. Rubin, and M. H66k.  1977. Binding of heparin and heparan 
sulfate to rat liver cells. Biochem. Biophys. Res. Commun. 74:126. 
61.  Glimelius, B., C. Busch, and M. H/~Jk.  1978. binding of heparin on the surface of cultured 
human endothelial ceils.  Thromb. Res. 12:773. 